Mitroflow DL Post Approval Study- North America

NATerminatedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Aortic StenosisAortic RegurgitationAortic Valve InsufficiencyHeart Valve DiseasesCardiovascular AbnormalitiesCardiovascular DiseasesCongenital AbnormalitiesHeart DiseasesPathological Conditions, Anatomical
Interventions
DEVICE

Mitroflow DL

Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)

Trial Locations (13)

19096

Lankenau Medical Center, Wynnewood

20814

Suburban Hospital - John Hopkins Medicine, Bethesda

22908

University of Virginia Medical Center, Charlottesville

27710

Duke University Medical Center, Durham

32207

River City Clinical Research, Jacksonville

32209

UF Health - Jacksonville, Jacksonville

33805

Watson Clinic Center for Research, Lakeland

48236

St. John Hospital & Medical Center, Detroit

48708

Bay Regional Medical Center, Bay City

90095

UCLA Medical Center, Los Angeles

92123

Sharp Memorial Hospital, San Diego

03102

Catholic Medical Center, Manchester

07503

St. Joseph's Regional Medical Center, Paterson

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LivaNova

INDUSTRY